Loading...
HER-2/neu overexpression in breast cancer
Background: In breast carcinoma, amplification &/or over-expression of HER-2/neu has been associated with a group of unfavorable prognostic factors. The Food & Drug Administration Agency approved Trastuzumab (Herceptin) for the therapy of metastatic breast cancer but only in patients with am...
Na minha lista:
Main Authors: | , |
---|---|
Format: | Artigo |
Sprog: | Inglês |
Udgivet: |
Faculty of Medicine University of Baghdad
2010-10-01
|
Serier: | مجلة كلية الطب |
Fag: | |
Online adgang: | http://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/977 |
Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|